medigraphic.com

2015, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (2)

Skin diseases and obesity

Guerra-Segovia C, Ocampo-Candiani J

Language: Spanish
References: 98
Page: 180-190
PDF size: 185.97 Kb.


ABSTRACT

Obesity is a public health problem worldwide. It predominates in industrialized countries; however, it is prevalent in all nations. It is defi ned as a condition of excess adipose tissue and is the result of changes in lifestyle, excessive consumption of energy-dense foods with poor nutritional value, physical inactivity and the reduction of open space where one can practice a sport.
Although obesity is associated with multiple diseases, it is important to stress that the metabolic changes caused by it affect skin physiology and play a predisposing factor for the development of skin diseases. Very little has been studied on the impact of obesity on the skin. The purpose of this article is to review the most frequently skin diseases in obesity. Some skin pathologies in obesity are caused by changes in skin physiology, others are related to insulin resistance or constitute an exacerbating factor for dermatitis. This article covers the clinical features of obesity related skin disease and its management.


REFERENCES

  1. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Re.s 2002;10(Suppl 2): S97-104.

  2. Garcia-Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol. 2002;3(7):497-506.

  3. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763-70.

  4. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin defi - ciency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903-8.

  5. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin defi ciency. N Engl J Med. 1999;341(12):879-84.

  6. Fine JB, Fine RM. Leptin levels in obesity. Int J Dermatol. 1997;36(10):727-8.

  7. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11):1407-33.

  8. Li P, Jin H, Liu D, Gao L, Xu Z, Nan W, et al. [Study on the effect of leptin on fi broblast proliferation and collagen synthesis in vitro in rats]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2005;19(1):20-2. Chinese.

  9. Goren I, Pfeilschifter J, Frank S. Determination of leptin signaling pathways in human and murine keratinocytes. Biochem Biophys Res Commun. 2003;303(4):1080-5.

  10. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401(6748):73-6.

  11. Bertagna X. Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am. 1994;23(3):467-85.

  12. Wintzen M, Yaar M, Burbach JP, Gilchrest BA. Proopiomelanocortin gene product regulation in keratinocytes. J Invest Dermatol. 1996;106(4):673-8.

  13. Yeo GS, Farooqi IS, Challis BG, Jackson RS, O’Rahilly S. The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models. QJM. 2000;93(1):7-14.

  14. Loffl er H, Aramaki JU, Effendy I. The infl uence of body mass index on skin susceptibility to sodium lauryl sulphate. Skin Res Technol. 2002;8(1):19-22.

  15. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE, et al. Obesity due to proopiomelanocortin defi ciency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab. 2003;88(10):4633-40.

  16. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol. 2001;137(11):1477-85.

  17. Cone RD. Haploinsuffi ciency of the melanocortin-4 receptor: part of a thrifty genotype?. J Clin Invest. 2000;106(2):185-7.

  18. Deplewski D, Rosenfi eld RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 1999;140(9):4089-94.

  19. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005;141(3):333-8.

  20. Zamboni S, Zanetti G, Grosso G, Ambrosio GB, Gozzetti S, Peserico A. Dietary behaviour in psoriatic patients. Acta Derm Venereol Suppl (Stockh). 1989;146:182-3.

  21. Rucevic I, Perl A, Barisic-Drusko V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol. 2003;27(Suppl. 1):41-8.

  22. Goodson WH 3rd, Hunt TK. Wound collagen accumulation in obese hyperglycemic mice. Diabetes. 1986;35(4):491-5.

  23. Rasmussen MH, Jensen LT, Andersen T, Breum L, Hilsted J. Collagen metabolism in obesity: the effect of weight loss. Int J Obes Relat Metab Disord. 1995;19(9):659-63.

  24. de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation. 2004;109(21):2529-35.

  25. Valensi P, Smagghue O, Pariés J, Velayoudon P, Lormeau B, Attali JR. Impairment of skin vasoconstrictive response to sympathetic activation in obese patients: infl uence of rheological disorders. Metabolism. 2000;49(5):600-6.

  26. Geffner ME, Golde DW. Selective insulin action on skin, ovary, and heart in insulin-resistant states. Diabetes Care. 1988;11(6):500-5.

  27. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and signifi cance of acanthosis nigricans in an adult obese population. Arch Dermatol. 1992;128(7):941-4.

  28. Grasinger CC, Wild RA, Parker IJ. Vulvar acanthosis nigricans: a marker for insulin resistance in hirsute women. Fertil Steril. 1993;59(3):583-6.

  29. Rendon MI, Cruz PD Jr, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol. 1989;21(3 Pt 1):461-9.

  30. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98(6 Suppl):S82-5.

  31. Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. Acta Diabetol. 2002;39(2):57-9.

  32. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm. Venereol. 1987;67(2):175-7.

  33. Tay YK, Kong KH, Khoo L, Goh CL, Giam YC. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol. 2002;146(1):101-6.

  34. Garcia-Hidalgo L, Orozco-Topete R, Gonzalez- Barranco J, Villa AR, Dalman JJ, Ortiz-Pedroza G. Dermatoses in 156 obese adults. Obes Res. 1999;7(3):299-302. 34. Yosipovitch G, Hodak E, Vardi P, Shraga I, Karp 189 Guerra-Segovia C et al. Dermatosis en la obesidad Rev Med Inst Mex Seguro Soc. 2015;53(2):180-90 M, Sprecher E, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care. 1998;21(4):506-9.

  35. Yosipovitch G, Mevorah B, Mashiach J, Chan YH, David M. High body mass index, dry scaly leg skin and atopic conditions are highly associated with keratosis pilaris. Dermatology. 2000; 20(1):34-6.

  36. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol. 1992;98(6 Suppl):S82-5.

  37. Ruutiainen K, Erkkola R, Grönroos MA, Irjala K. Infl uence of body mass index and age on the grade of hair growth in hirsute women of reproductive ages. Fertil Steril. 1988;50(2):260-5.

  38. Scheinfeld NS. Obesity and dermatology. Clin Dermatol. 2004;22(4):303-9.

  39. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1360-5.

  40. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab. 2005;90(1):60-5.

  41. Rogalski C, Haustein UF, Glander HJ, Paasch U. Extensive striae distensae as a result of topical corticosteroid therapy in psoriasis vulgaris. Acta Derm Venereol. 2003;83(1):54-5.

  42. Hsu HS, Chen W, Chen SC, Ko FD. Colored striae in obese children and adolescents. Zhonghua Min Guo. Xiao Er Ke Yi Xue Hui Za Zhi.1996;37(5):349-52.

  43. Simkin B, Arce R. Steroid excretion in obese patients with colored abdominal striae. N Engl J Med. 1962 May 17;266:1031-5.

  44. Kang S. Topical tretinoin therapy for management of early striae. J Am Acad Dermatol. 1998;39(2 Pt 3):S90-2.

  45. Pribanich S, Simpson FG, Held B, Yarbrough CL, White SN. Low-dose tretinoin does not improve striae distensae: a double-blind, placebo-controlled study. Cutis.1994;54(2):121-4.

  46. Hernández-Pérez E, Colombo-Charrier E, Valencia- Ibiett E. Intense pulsed light in the treatment of striae distensae. Dermatol Surg. 2002;28(12):1124-30.

  47. Jiménez GP, Flores F, Berman B, Gunja-Smith Z. Treatment of striae rubra and striae alba with the 585-nm pulsed-dye laser. Dermatol Surg. 2003;29(4):362-5.

  48. Goldberg DJ, Sarradet D, Hussain M. 308-nm Excimer laser treatment of mature hypopigmented striae. Dermatol Surg. 2003;29(6):596-8.

  49. Nouri K, Romagosa R, Chartier T, Bowes L, Spencer JM. Comparison of the 585 nm pulse dye laser and the short pulsed CO2 laser in the treatment of striae distensae in skin types IV and VI. Dermatol Surg. 1999;25(5):368-70.

  50. Dercum FX. Three cases of a hitherto unclassifi ed affection resembling in its grosser aspects obesity, but associated with special nervous symptoms-adiposis dolorosa. Am J Med Sci. 1892; 104(6):521-35.

  51. Brodovsky S, Westreich M, Leibowitz A, Schwartz Y. Adiposis dolorosa (Dercum’s disease): 10-year follow-up. Ann Plast Surg. 1994;33(6):664-8.

  52. DeFranzo AJ, Hall JH Jr, Herring SM. Adiposis dolorosa (Dercum’s disease): liposuction as an effective form of treatment. Plast Reconstr Surg. 1990;85(2):289-92.

  53. Amine B, Leguilchard F, Benhamou CL. Dercum’s disease (adiposis dolorosa): a new case-report. Joint Bone Spine. 2004;71(2):147-9.

  54. Palmer ED. Dercum’s disease: adiposis dolorosa. Am Fam Physician. 1981;24(5):155-7.

  55. Iwane T, Maruyama M, Matsuki M, Ito Y, Shimoji K. Management of intractable pain in adiposis dolorosa with intravenous administration of lidocaine. Anesth Analg. 1976;5582):257-9.

  56. Petersen P, Kastrup J. Dercum’s disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine. Pain. 1987;28(1):77-80.

  57. Schissel DJ, Hivnor C, Elston DM. Elephantiasis nostra verrucosa. Cutis. 1998;62(2):77-80.

  58. Chernosky ME, Derbes VJ. Elephantiasis nostras of the abdominal wall. Arch Dermatol. 1966;94(6):757-62.

  59. Ko DS, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Arch Surg. 1998;133(4):452-8.

  60. Lacroix P, Aboyans V, Preux PM, Houles MB, Laskar M. Epidemiology of venous insuffi ciency in an occupational population. Int Angiol. 2003;22(2):172-6.

  61. Padberg F Jr, Cerveira JJ, Lal BK, Pappas PJ, Varma S, Hobson RW 2nd. Does severe venous insuffi ciency have a different etiology in the morbidly obese? Is it venous?. J Vasc Surg. 2003;37(1):79-85.

  62. Angle N, Freischlag JA. Venous disease. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, editors. Sabiston textbook of surgery. 17th ed. London (UK): Elsevier; 2004. p. 2060.

  63. Bull RH, Mortimer PS. Acute lipodermatosclerosis in a pendulous abdomen. Clin Exp Dermatol. 1993;18(2):164-6.

  64. Abbade LP, Lastória S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005;44(6):449-56.

  65. Smith PC, Sarin S, Hasty J, Scurr JH. Sequential gradient pneumatic compression enhances venous ulcer healing: a randomized trial. Surgery. 1990;108(5):871-5.

  66. Jull A, Waters J, Arroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet. 2002;359(9317):1550-4.

  67. Birtane M, Tuna H. The evaluation of plantar pressure distribution in obese and non-obese adults. Clin Biomech (Bristol Avon). 2004;19(10):1055-9.

  68. Mann RA, Mann JA. Keratotic disorders of the plantar skin. Instr Course Lect. 2004;53:287-302.

  69. Rossi AB, Vergnanini AL. Cellulite: a review. J Eur Acad Dermatol Venereol. 2000;14(4):251-62.

  70. Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. Diabetes Care. 1993;16(4):560-3.

  71. Odds FC. Ecology and epidemiology of Candida species. Zentralbl Bakteriol Mikrobiol Hyg A. 1984;257(2):207-12.

  72. Chapman MS, Brown JM, Linowski GJ. 0.1 % tacrolimus ointment for the treatment of intertrigo. Arch Dermatol. 2005;141(6):787.

  73. Chan MK, Chong LY; Achilles Working Group in Hong Kong. A prospective epidemiologic survey on the prevalence of foot disease in Hong Kong. J Am Podiatr Med Assoc. 2002;92(8):450-6.

  74. Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl). 2002;115(6):860-5.

  75. Gupta AK, Ryder JE, Lynch LE, Tavakkol A. The use of terbinafi ne in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol. 2005;4(3):302-8.

  76. Vaillant L, Gironet N. [Infectious complications of lymphedema]. Rev Med Interne. 2002;23(Suppl 3):S403-7. French.

  77. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591-4.

  78. Zaraa I, Zeglaoui F, Zouari B, Ezzine N, Fazaa B, Kamoun MR. [Erysipelas. Retrospective study of 647 patients]. Tunis Med. 2004;82(11):990-5. French.

  79. Granier F. [Management of erysipelas]. Ann Dermatol Venereol. 2001;128(3 Pt 2):429-42. French.

  80. Gozal D, Ziser A, Shupak A, Ariel A, Melamed Y. Necrotizing fasciitis. Arch Surg. 1986;121(2):233-5.

  81. Francis KR, Lamaute HR, Davis JM, Pizzi WF. Implications of risk factors in necrotizing fasciitis. Am Surg. 1993;59(5):304-8.

  82. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J. 1997;90(11):1065-8.

  83. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother. 2004;5(8):1767-70.

  84. Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003;56(5):451-61.

  85. Jansen I, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol. 2001;15(6):532-40.

  86. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971-4.

  87. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325-8.

  88. Lebwohl B, Sapadin AN. Infl iximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003; 49(5 Suppl):S275-6.

  89. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infl iximab for hidradenitis suppurativa. Br J Dermatol. 2003;149(5):1046-9.

  90. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infl iximab infusion. Arch Dermatol. 2003;139(12):1540-2.

  91. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infl iximab in a patient with Crohn’s disease. J Dermatolog Treat 2005;16(1):58-61.

  92. Banerjee AK. Surgical treatment of hidradenitis suppurativa. Br J Surg. 1992;79(9):863-6.

  93. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527-34.

  94. Hamminga EA, van der Lely AJ, Neumann H, Thio HB. Chronic infl ammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768-73.

  95. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-6.

  96. Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal RJ. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14(8):1132-4.

  97. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136(5):609-16.

  98. Shafi q N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005;44(4):328-33.




2020     |     www.medigraphic.com